Latest News

doctor filling biosimilar syringe| Image credit: PhotobyTawat
No Differences in Treatment Persistence, Safety Detected for Anti-TNF Biosimilars vs Originators

June 22nd 2024

A real-world study using data from the French National Health Data System, found no significant differences in treatment persistence or safety between anti-tumor necrosis factor (TNF)-α biosimilars and reference products in all indications of these biologics.

FDA | Image credit: wladimir1804 -
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability

June 20th 2024

canada biosimilars | Image credit: Rawf8 -
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years

June 18th 2024

child with inflammatory bowel disease | Image credit: zinkevych -
Real-World Study: Nonmedical Switch to Infliximab Biosimilar Is Safe, Effective in Pediatric Patients With IBD

June 12th 2024

doctor and patient | Image credit: sebra -
Switching Patients With IBD to Infliximab, Adalimumab Biosimilars Did Not Impact Efficacy

June 8th 2024

Video Series
Video Interviews
CFB podcast banner
CFB podcast banner
CFB podcast banner
CFB podcast banner
CFB podcast banner
CFB podcast banner
CFB podcast banner
cfb podcast banner
"When Choice Arrives: Competition & Consequences" written over a bright blue syringe with the AJMC/The Center for Biosimilars logo in the bottom right corner

More News

© 2024 MJH Life Sciences

All rights reserved.